제논 파마슈티컬스(XENE)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $62.35 (-2.93%), 시가총액 $5.26B, 52주 범위 $28.49 ~ $62.76.
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeti
제논 파마슈티컬스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
제논 파마슈티컬스의 현재 주가는 $62.35 (-2.93%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
제논 파마슈티컬스의 시가총액은 약 $5.26B입니다.
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric di